Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Keystone

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Rheumatology. Supplement|May 4, 2010
Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseasesBrian Bressler, Boulos Haraoui, Edward Keystone, et al.
Arthritis and Rheumatism|December 2, 2005
The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposesFrederick Wolfe, Kaleb Michaud, Theodore Pincus, et al.
The Journal of Rheumatology|February 21, 2009
Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RAEdward Keystone, Bruce Freundlich, Michael Schiff, et al.
Clinical and Experimental Rheumatology|June 10, 2024
Impact of anti-rheumatic treatment on the individual components of the ACR composite score in patients with rheumatoid arthritis: real-world dataMohammad Movahedi, Denis Choquette, Louis Coupal, et al.
Plos One|May 6, 2021
Health care costs of rheumatoid arthritis: A longitudinal population studyMark Tatangelo, George Tomlinson, J Michael Paterson, et al.
Arthritis Care & Research|April 13, 2011
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegolTheodore Pincus, Victoria Furer, Edward Keystone, et al.
Rheumatology and Therapy|November 10, 2021
Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19Andrew J Holman, Edward Keystone, Ernest Choy, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 30, 2023
Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis?Louis Bessette, Mohammad Movahedi, George Reed, et al.
Arthritis Research & Therapy|July 1, 2005
Somatic mutations in the mitochondria of rheumatoid arthritis synoviocytesTanya R Da Sylva, Alison Connor, Yvonne Mburu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatmentRieke Alten, Jeffrey Kaine, Edward Keystone, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Rheumatology. Supplement|May 4, 2010
Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseasesBrian Bressler, Boulos Haraoui, Edward Keystone, et al.
Arthritis and Rheumatism|December 2, 2005
The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposesFrederick Wolfe, Kaleb Michaud, Theodore Pincus, et al.
The Journal of Rheumatology|February 21, 2009
Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RAEdward Keystone, Bruce Freundlich, Michael Schiff, et al.
Clinical and Experimental Rheumatology|June 10, 2024
Impact of anti-rheumatic treatment on the individual components of the ACR composite score in patients with rheumatoid arthritis: real-world dataMohammad Movahedi, Denis Choquette, Louis Coupal, et al.
Plos One|May 6, 2021
Health care costs of rheumatoid arthritis: A longitudinal population studyMark Tatangelo, George Tomlinson, J Michael Paterson, et al.
Arthritis Care & Research|April 13, 2011
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegolTheodore Pincus, Victoria Furer, Edward Keystone, et al.
Rheumatology and Therapy|November 10, 2021
Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19Andrew J Holman, Edward Keystone, Ernest Choy, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 30, 2023
Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis?Louis Bessette, Mohammad Movahedi, George Reed, et al.
Arthritis Research & Therapy|July 1, 2005
Somatic mutations in the mitochondria of rheumatoid arthritis synoviocytesTanya R Da Sylva, Alison Connor, Yvonne Mburu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatmentRieke Alten, Jeffrey Kaine, Edward Keystone, et al.
Pageof 9